Ipsen concludes purchase of Albireo Pharma
Pharmaceutical Technology
MARCH 3, 2023
French biopharmaceutical firm Ipsen has concluded the purchase of US-based Albireo Pharma , expanding its rare disease portfolio. Albireo’s pipeline includes its lead asset, Bylvay (odevixibat), a potent, once-a-day, oral, non-systemic, ileal bile acid transport inhibitor (IBATi).
Let's personalize your content